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Abstract
Dendritic cells (DC) are the only hematopoietic cells expressing the epithelial specific Ets transcription factor ESE-3. Here we
analyzed presence and quantity of isoforms ESE-3a, ESE-3b and ESE-3j in various immunogenic and tolerogenic human
monocyte-derived DC (moDC) and blood DC populations using quantitative real time PCR and immunoblot analyses. ESE-3a
and ESE-3b were detectable in all moDC populations with ESE-3b being the main transcript. ESE-3b expression was
upregulated in immunogenic moDC and downregulated in tolerogenic moDC compared to immature moDC. ESE-3a had
similar transcript levels in immature and immunogenic moDC and had very low levels in tolerogenic moDC. In blood DC
populations only splice variant ESE-3b was detectable. ESE-3j was not detectable in any of the DC populations. These
findings suggest that ESE-3b is the functionally most important ESE-3 isoform in DC.
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Introduction
Dendritic cells (DC) are the most potent antigen presenting cells
with the unique ability to induce and maintain primary immune
responses [1]. In the periphery, DC acquire antigens and migrate
to the lymph nodes where peptide antigens are presented to T
lymphocytes. During this pathway, immature DC, capable of
antigen uptake, differentiate into mature DC. Mature DC are
characterized by high surface expression of MHC class II and co-
stimulatory molecules able to induce an immune response.
Furthermore, DC play an important role in tolerance induction
[2] as immature DC within peripheral tissues continuously sample
the surroundings for antigens, e.g. from apoptotic cells. In the
absence of maturation stimuli, DC present self-peptide-MHC
complexes to circulating naive T cells in peripheral lymphoid
organs. In the case of autoreactivity, the T cells will be deleted or
become anergic, thereby avoiding autoimmunity [3–5].
Due to the outstanding capacity of DC to process and present
antigenic peptides to T lymphocytes, several concepts have been
developed to use DC in cancer immunotherapy. The basic idea is
to generate sufficient amounts of immunogenic DC from
progenitor cells ex vivo, load them with tumor specific antigens
and re-inject them into the patient where they are then supposed
to initiate an immune response towards the tumor cells [6,7].
Though the theory behind it is very logical, these therapeutic
approaches have only shown modest results in the clinic so far
[8,9]. The choice of the DC population has been suggested to be
very important in the success of the vaccine [10,11]. Moreover,
during the past few years, the possibility to utilize tolerogenic DC-
based vaccines as a clinical modality to treat autoimmune diseases
has been investigated with promising results in mouse models [12–
14].
We have previously reported that the transcription factor ESE-3
is involved in the development of monocyte-derived DC (moDC)
[15]. ESE-3 (also known as EHF) belongs to the family of E26
transformation specific (Ets) transcription factors. Members of the
Ets family are characterized by a conserved winged helix-turn-
helix DNA binding domain called Ets domain enabling them to
bind the core DNA sequence 59-GGA(A/T)-39 [16]. Several
members of the Ets family are proto-oncogenes involved in cancer
development and tumor invasion [17,18]. Others play crucial roles
in the proliferation as well as in differentiation of epithelial and
hematopoietic cells [19,20]. To name a few, it was shown that
PU.1 and Ets1 are important in T cell development [21].
Regarding DC, PU.1 is required for development of myeloid-
derived but not for lymphoid-derived DC [22]. Moreover, Spi-B
expression seems to be crucial during development of human
plasmacytoid DC [23].
ESE-3 [24] belongs to the epithelial specific subset of Ets
transcription factors, including ESE-1 (also known as ELF-3) [25]
and ESE-2 (also known as ELF-5) [26]. ESE-1 and ESE-3 have
been shown to be involved in the regulation of allergic airway
inflammation [27,28]. Furthermore, a genome-wide association
study has found linkage of cystic fibrosis lung disease severity with
a locus near the ESE-3 gene on chromosome 11p13 [29],
suggesting that ESE-3 might be involved in regulating cell
differentiation in the airways. Moreover, it was recently described
that DC from ESE-12/2 mice produce reduced amounts of IL-6
resulting in impaired Th17 differentiation in these animals [28].
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Epithelial cells have important functions in balancing immune
responses and immune tolerance. Different pathways are involved
in promoting changes in cytokine and chemokine secretion by
epithelial cells as well as in the display of molecules on the surface
of epithelial cells [30]. Interestingly, ESE-3 expression in bronchial
epithelial cells is upregulated by the inflammatory cytokines IL-1b
and TNF-a. Since ESE-3 expression was shown in epithelial as
well as in dendritic cells [15,31] it is tempting to link the role of
ESE-3 directly to the immunoregulating functions of these two cell
types. However, the role of ESE-3 in the transcriptional networks
in these cells has yet to be assessed.
ESE-3 is a transcriptional repressor of several genes that are
positively regulated by MAP kinase signalling [31]. ESE-3 requires
high affinity binding sites with the suggested consensus sequence
59-AGGAAGT-39 [31]. Moreover, downregulation of ESE-3 has
been described to be involved in prostate tumorigenesis [32,33].
Albino and colleagues recently showed that loss of ESE-3 induces
epithelial-to-mesenchymal transition in prostate epithelial cells,
suggesting ESE-3 to be a key regulator in the development of
prostate cancer [33]. On the other hand, overexpression of ESE-3
was reported in ovarian cancer [34] and has therefore been
proposed as a predictive marker for poor survival of patients [35].
It has also been suggested that survival of colon tumor cells
containing wild-type p53 are dependent on overexpression of
ESE-3 [36].
The function of ESE-3 during the development and maturation
of DC is still elusive. Knockdown experiments using siRNA
suggest that ESE-3 is crucial during moDC development. In
addition, it was shown that DC are the only hematopoietic cells
that express this transcription factor [15].
Not much is known about the different isoforms of ESE-3. Until
now, three different transcript variants have been identified
(Figure 1). They encode three different isoforms, ESE-3a
(GenBank acc.-no. NM_001206615), ESE-3b (GenBank acc.-no.
NM_012153) and ESE-3j (GenBank acc.-no. NM_001206616).
ESE-3j is the longest transcript with an alternative exon 1 and start
codon as ESE-3a and ESE-3b. ESE-3a is the shortest transcript
lacking exon 6 which encodes 23 amino acids. Sequence analyses
disclosed an open reading frame encoding 277 amino acids with a
calculated molecular weight of 32 kDa for ESE-3a, 300 amino
acids with a calculated molecular weight of 35 kDa for ESE-3b
[24] and 322 amino acids with a calculated molecular weight of
37 kDa for ESE-3j. Computer based analyses failed to predict any
functional properties for the domain that is removed in ESE-3a.
Exons 2 and 3 encode a pointed domain responsible for protein-
protein interactions, exons 8 and 9 encode the DNA-binding Ets
domain constituting the winged helix-turn-helix motif (Figure 1).
For improvement of DC based immunotherapy it is crucial to
get a better understanding of the molecular mechanism involved
in DC development and maturation. Here, we demonstrate that
ESE-3a and ESE-3b isoforms are present in various moDC
populations with full-length ESE-3b being the main isoform also
present in blood DC populations. ESE-3j was not detected in any
DC population analyzed. ESE-3b expression was upregulated in
immunogenic moDC and downregulated in tolerogenic moDC
suggesting an important function in immunogenic DC.
Materials and Methods
Generation of Monocyte Derived DC
Buffy coat preparations from healthy blood donors (Blood Bank,
Haukeland University Hospital, Bergen, Norway) were used as a
source for monocytes as described previously [37]. Briefly,
mononuclear cells from peripheral blood were isolated by density
gradient centrifugation followed by a negative selection of
monocytes using the Dynabeads Untouched Human Monocytes
Kit (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. For the generation of immature moDC, monocytes
were cultured in RP10 medium [RPMI 1640 (Cambrex Biosci-
ence, Verviers, Belgium), supplemented with 10% FCS (PAA,
Pasching, Austria), 100 units/ml penicillin and 100 mg/ml
streptomycin (Sigma-Aldrich, St Louis, MO), IL-4 (20 ng/ml;
ImmunoTools, Friesoythe, Germany) and GM-CSF (100 ng/ml;
ImmunoTools)] for 6 days. The cytokines were replenished every
2–3 days. To generate immunogenic DC, immature DC were
stimulated with LPS (1 mg/ml; Sigma-Aldrich), polyI:C (50 mg/
ml; Sigma-Aldrich), and with a cytokine cocktail containing TNF-
a (10 ng/ml; ImmunoTools), IL-1b (10 ng/ml; ImmunoTools),
IL-6 (1000 U/ml; ImmunoTools) and PGE2 (1 mg/ml; Sigma-
Aldrich), respectively, for 24 h. For the generation of two
tolerogenic DC populations, IL-4, GM-CSF and 15d-PGJ2
(5 mM; Biomol, Hamburg, Germany) were added to one
population of monocytes from day 0 and replenished every 2–3
days (PGJ2-DC), and IL-4, GM-CSF (from day 0), dexamethasone
(day 3 and 6; 1026 M; Sigma-Aldrich) and 1a,25-dihydroxyvita-
min D3 (day 6; 10210 M; Sigma-Aldrich) were added to another
cell population (Dex/VD3 DC).
Isolation of DC From Peripheral Blood
Peripheral blood DC populations [type-1 myeloid DC (mDC1),
type-2 myeloid DC (mDC2) and plasmacytoid DC (pDC)] were
isolated from buffy coat preparations from healthy donors (Blood
Bank, Haukeland University Hospital) using magnetic cell sorting
(MACS) technology according to the manufacturer’s protocols
(CD1c Dendritic Cell Isolation Kit, CD141 MicroBead Kit,
CD304 MicroBead Kit, all from Miltenyi Biotec, Bergisch
Gladbach, Germany).
Figure 1. Exon composition of ESE-3 transcript variants. Exons are marked with numbers 1–9. Critical exons for distinction between the splice
variants are color-coded. The different domains and translational start (R) and stop (| ) are marked. An alternative exon 1a distinguishes ESE-3j from
ESE-3a and ESE-3b. Translation of ESE-3j is initiated in exon 1a, whereas translation of ESE-3a and ESE-3b starts in exon 2. ESE-3a is the shortest
transcript variant owing to the lack of exon 6.
doi:10.1371/journal.pone.0049577.g001
ESE-3b is the Main ESE-3 Isoform in Human DC
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e49577
Figure 2. Overexpressed ESE-3a and ESE-3b are located in the nucleus of HeLa cells. HeLa cells were transfected with expression vectors
coding for ESE-3a-EGFP and ESE-3b-EGFP. After 24 h, cells were fixed and subjected to immunocytochemistry using a monoclonal antibody specific
for human ESE-3. The ESE-3a- and ESE-3b-constructs localized exclusively to the nucleus as revealed by both the intrinsic green fluorescence and the
ESE-3 immunoreactivity. One representative experiment out of three is shown. Scale bar: 50 mM.
doi:10.1371/journal.pone.0049577.g002
ESE-3b is the Main ESE-3 Isoform in Human DC
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RNA Isolation, cDNA Synthesis, PCR and Real-time RT-PCR
Total RNA was isolated using the RNeasy Mini or RNeasy Plus
Mini Kit (QIAGEN, Hilden, Germany) following the manufac-
turer’s protocol. Up to 2 mg total RNA was used in a 20 ml cDNA
synthesis reaction using RevertAid Reverse Transcriptase (Fer-
mentas, St. Leon-Rot, Germany) according to the manufacturer’s
recommendations. Two reactions were performed for each sample
using Oligo(dT)18 primer and random hexamer primer. The two
reactions were pooled afterwards. For analyzing ESE-3j expres-
sion, a PCR with 35 cycles was performed using the primers ESE-
3j fwd: 59- GTTGCCGGAGAGAAGAGGAT and ESE-3j rev:
59- GGTCCAGTACTGAGGATGAAT and approximately
50 ng of cDNA as template. The same amount of cDNA was
used to analyze ESE-3a and ESE-3b transcript levels in a
quantitative real-time RT-PCR using Taqman technology. For
detection an ABI 7500 real time PCR system (Applied Biosystems,
Carlsbad, USA) was used. The reactions were run in duplicates.
Primer and probes used were as follows: ESE-3a FP: 59-TGAA-
CACCTGGAAAGACGAGAA, ESE-3a RP: 59-AGTGAGTCCC-
TCTCGGGTTGT, ESE-3a probe: 59-[6FAM]TCATATCAGGT-
GACTCTGCTACTGTGCTACCATAGT[BHQ1], ESE-3b FP:
59-CTATGGTAGCACAGTAGATTT GTTGGA, ESE-3b RP:
59-GACTCTGCAACAGGAAGGTGACT, ESE-3b probe: 59-
[6FAM]TCTGCCGGGCTCAGATCTCCATGA[BHQ1], GAP-
DH FP: 59-CCACATCGCT CAGACACCAT, GAPDH RP: 59-
GGCAACAATATCCACTTTACCAGAGT, and GAPDH Probe:
59-[6FAM]ACCAAATCCGTTGACTCCGACCTTCA[BHQ1].
For each RT-PCR reaction 16104 copies from ESE-3a pEGFP-N1
and ESE-3b pEGFP-N1was included as control for specificity and
efficiency of the primer/probe combination. Transcript levels of
GAPDH were used for normalization. To determine the relative
expression of the ESE-3 isoforms in the different moDC populations,
immature moDC were used as reference.
Figure 3. Phenotypic characterization of immunogenic and tolerogenic moDC populations by flow cytometry. Monocytes were
negatively selected from PBMC using magnetic beads. Immature moDC were generated with IL-4 and GM-CSF for 6 days. 15d-PGJ2 (PGJ2 DC) and
dexamethasone plus 1a,25-dihydroxyvitamin were added to generate tolerogenic moDC, respectively (PGJ2 DC and Dex/VD3 DC). To generate
immunogenic moDC, immature moDC were stimulated for 24 h with LPS, polyI:C and a cytokine cocktail containing TNF-a, IL-1b, IL-6 and PGE2,
respectively. The phenotypes of the cells were analyzed by flow cytometry. Live cells were gated according to FSC/SSC. One representative
experiment out of three is shown.
doi:10.1371/journal.pone.0049577.g003
ESE-3b is the Main ESE-3 Isoform in Human DC
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Western Blotting
56105 cells were used to prepare nuclear extracts as described
previously [38]. Approximately 20 mg nuclear extract were loaded
on each lane of a 12% sodium dodecyl sulfate (SDS)-polyacryl-
amide gel and transferred to a nitrocellulose membrane (Bio-Rad
Laboratories, Hercules, CA). Membranes were stained with
Ponceau S solution to confirm equal amounts of protein in each
lane. This was verified by using a histone H3 antibody (D1H2,
Cell Signalling, Boston, MA) in one experiment. The blot was
probed over night at 4uC with a monoclonal rat anti ESE-3
antibody (5A5.5, Lifespan, Seattle, WA) diluted 1:200. As
secondary antibody a HRP-coupled goat anti rat antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) was used in a 1:1000
dilution. Signal West Femto was used as substrate (Pierce, Thermo
Fisher Scientific, Rockford, IL). Proteins were visualized with a
ChemicDoc XRS system and analyzed with Quantity One
software (both from Bio-Rad Laboratories).
Flowcytometry
Immunostaining was performed to determine the phenotype of
the different DC populations. Cells were incubated with FcR-
block (Miltenyi Biotec, 2,5 ml/16105 cells, 10 min, room temper-
ature) followed by incubation with titrated amounts of antibodies
(10 min, room temperature). Subsequently the cells were washed
and analyzed on a LSRFortessa Cell Analyzer (BD Biosciences,
Heidelberg, Germany). The following antibodies were used:
CD1a-PE (HI 149, ImmunoTools), CD14-FITC (18D11, Im-
munoTools), HLA-DR-APC (HL-39; AbD Serotec, Düsseldorf,
Germany), CD86-FITC (BU63; AbD Serotec), CD83-PE (HB15,
AbD Serotec), CD80-APC (MEM-233, ImmunoTools). FlowJo
software (Tree Star, Ashland, OR) was used for the analysis. In the
negative control samples 1% false-positive events were accepted
throughout the experiments.
Cloning of ESE3a and ESE3b into pEGFP-N1
For the full-length isoform ESE-3b, the primers ESE3 fwd:
59-GGCGGCTAGCCACCATGATTCTGGAAGGAGGTGG/
ESE3 rev: 59-GCGGACCGGTCCGTTTTCATTTTCTCTC-
CATCC were used with cDNA from moDC as template. NheI/
AgeI was used for cloning into pEGFP-N1 (Clontech, Saint-
Germain-en-Laye, France).
For the ESE3a isoform two amplicons were generated using the
primers ESE3fwd: 59-GGCGGCTAGCCACCATGATTCTG-
GAAGGAGGTGG/ESE3rev splice variant: 59- TACT GTGC-
TACCATAGTTGG and ESE3fwd splice variant: 59-GCA-
GAGTCACCTGATATGAA/ESE3rev: 59-GCGGACCGGTC-
CGTTTTCATTTTCTCTCCATCC. The longer fragment
(ESE3fwd/ESE3rev splice variant) was phosphorylated and the
two fragments were ligated. A new PCR was performed using the
ligated fragments as template and the primers ESE3fwd/ESE3rev.
NheI/AgeI was used to clone the product into pEGFP-N1. Both
constructs, ESE3a-pEGFP-N1 and ESE3b-pEGFP-N1, were
Figure 4. ESE-3b is the main ESE-3 isoform in moDC. Monocytes were negatively selected from PBMC using magnetic beads. Immature moDC
were generated with IL-4 and GM-CSF for 6 days. 15d-PGJ2 (PGJ2 DC) and dexamethasone plus 1a,25-dihydroxyvitamin were added to generate
tolerogenic moDC, respectively (PGJ2 DC and Dex/VD3 DC). To generate immunogenic moDC, immature moDC were stimulated for 24 h with LPS,
polyI:C and a cytokine cocktail containing TNF-a, IL-1b, IL-6 and PGE2, respectively. ESE-3a and ESE-3b mRNA levels were determined by quantitative
RT-PCR analyses. (A) Primers and probes used for quantitative real-time RT PCR are marked. Exons are color-coded as in Figure 1. Positions of the base
pairs of the open reading frames are indicated by numbers. (B) Relative amounts of ESE-3a and ESE-3b cDNA in various moDC populations. Transcript
levels of GAPDH were used to calculate delta Ct values. Lower delta Ct values indicate higher amounts of target mRNA. N = 4–6. Significant
differences between delta Ct values of ESE-3a and ESE-3b within the same moDC population are indicated. ***p,0.001.
doi:10.1371/journal.pone.0049577.g004
ESE-3b is the Main ESE-3 Isoform in Human DC
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transformed into JM109 cells. Positive clones were selected using
LB-plates containing kanamycin. Correct clones were confirmed
by sequencing.
Immunocytochemistry
HeLa-S3 cells (DSMZ, Braunschweig, Germany) were cultured
in DMEM medium (Gibco, Invitrogen) with 10% FCS (PAA), 100
units/ml penicillin and 100 mg/ml streptomycin (both Sigma-
Aldrich). Transfection was performed in a 24 well plate using
Effectene Transfection Reagent (QIAGEN, Hilden, Germany)
according to the manufacturer’s protocol. After 24 h cells were
fixed for 30 minutes with ice cold 4% formaldehyde (Sigma-
Aldrich) and permeabilized with 0.5% Triton X-100 (Sigma-
Aldrich) for 15 minutes at room temperature. After blocking with
10% FCS (1 h, room temperature), a 1:200 dilution of rat anti-
ESE3 antibody (5A5.5, Lifespan) in 10% FCS was added to the
fixed cells and incubated over night at 4uC. For detection, a
secondary Texas Red-x goat anti-rat IgG antibody (Invitrogen)
was added for 1 h at room temperature in a 1:1000 dilution.
Nuclei were stained using DAPI (0.5 mg/ml).
Statistical Analyses
All statistical analyses were performed with Prism (GraphPad
software Inc., La Jolla, CA). Wilcoxon signed rank test was applied
to analyze differences in the median of relative mRNA levels of
moDC populations, a one-way analysis of variance (ANOVA) was
used to analyze differences in delta Ct values in the different blood
DC populations, and a 2-way ANOVA with Bonferroni post-test
was utilized to analyze differences in delta Ct values for ESE-3a
and ESE-3b expression within each moDC population. A p
value,0.05 was considered statistically significant.
Results
Overexpressed ESE-3a and ESE-3b is Located in the
Nucleus of HeLa Cells
ESE-3 is a transcription factor and should therefore be located
in the nucleus of cells when active. However, the DNA-sequences
of all ESE-3 splice variants lack a nuclear localization signal. Here
we wanted to investigate if changes in the primary structures of the
ESE-3 isoforms have an impact on cellular localization. Since
there are no isoform-specific ESE-3 antibodies available we
Figure 5. ESE-3b expression is increased in immunogenic moDC. Monocytes were negatively selected from PBMC using magnetic beads.
Immature moDC were generated with IL-4 and GM-CSF for 6 days. 15d-PGJ2 (PGJ2 DC) and dexamethasone plus 1a, 25-dihydroxyvitamin were added
to generate tolerogenic moDC, respectively (PGJ2 DC and Dex/VD3 DC). To generate immunogenic moDC, immature moDC were stimulated for 24 h
with LPS, polyI:C and a cytokine cocktail containing TNF-a, IL-1b, IL-6 and PGE2, respectively. (A) ESE3a and (B) ESE-3b mRNA levels were analyzed by
quantitative real-time RT PCR using isoform specific primer/probes. GAPDH was used for normalization, immature moDC were used as reference.
N = 4–6, *p,0.05. (C) Protein levels of ESE-3 in nuclear extracts were analyzed by Western blotting using a monoclonal antibody specific for human
ESE-3. Histone H3 was included to ensure equal loading of the gel. One representative experiment out of three is shown.
doi:10.1371/journal.pone.0049577.g005
ESE-3b is the Main ESE-3 Isoform in Human DC
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transiently expressed C-terminally EGFP-fused ESE-3a and ESE-
3b constructs in HeLa cells. One day post transfection both
proteins were exclusively localized to the nucleus as revealed by
both the intrinsic green fluorescence and by ESE-3 immunocy-
tochemistry (Figure 2). Nuclei were additionally stained with DAPI
(data not shown).
ESE-3a and ESE-3b are Transcribed in Human moDC with
ESE-3b being the Main Transcript Upregulated Upon
Stimulation of DC
We next wanted to compare transcript levels of ESE-3a, ESE-
3b and ESE-3j in various immunogenic and tolerogenic moDC
populations. The phenotype of the generated moDC populations
was verified by flow cytometry (Figure 3). As expected, moDC
matured with the cytokine cocktail, LPS or polyI:C had high
expression of CD1a and CD80, upregulation of CD83, CD86 and
HLA-DR compared to immature DC, and had lost CD14
expression. Tolerogenic DC generated with Dex/VD3 showed
high expression of CD1a, CD80 and HLA-DR. Compared to
immature DC they showed a slight increase of CD83 expression
but no upregulation of CD86 on their surface. In addition, they
still expressed monocyte marker CD14. MoDC generated in the
presence of PGJ2 had a reduced expression of CD1a, HLA-DR,
CD80, CD83 and CD86 compared to immature moDC and were
slightly positive for CD14.
For verification of the amplification efficiency of the primer/
probe combinations (Figure 4A) we conducted control reactions
with plasmid DNA harboring the open reading frames of ESE-3a
and ESE-3b, respectively (data not shown). Analyzing transcript
levels of the splice variants ESE-3a and ESE-3b showed that ESE-
3b was the main transcript in all moDC populations determined
by lower delta Ct values compared to ESE-3a (Figure 4B).
ESE-3j could not be detected in any moDC population
analyzed by conventional PCR (data not shown).
ESE-3b, but not ESE-3a transcription was significantly
upregulated upon stimulation of the cells (Figure 5A, B). Presence
of Dex/VD3 and PGJ2 during moDC generation resulted in
decreased amounts of ESE-3a and ESE-3b mRNA compared to
immature moDC (Figure 5A, B). Particular in the DC population
treated with Dex/VD3, ESE-3a was hardly detectable (Ct values
around 40).
In order to confirm the differential expression of the ESE-3
isoforms on protein level, we analyzed isolated nuclei for ESE-3
expression by Western blot using an antibody recognizing all ESE-
3 isoforms. Only one band corresponding to ESE-3b was
detectable on the blots (Figure 5C). Strong immunoreactivity of
ESE-3 was detectable in nuclei of immunogenic moDC popula-
tions with moDC matured with LPS or polyI:C giving the highest
signal. Both tolerogenic moDC populations showed almost no
ESE-3b expression confirming the real time RT-PCR results.
ESE-3b is the Only ESE-3 Isoform Transcribed in Blood DC
To investigate if the results obtained from moDC populations
were similar for blood DC populations, we isolated mDC1, mDC2
and pDC from buffy coat blood. In all three blood DC
populations, only ESE-3b mRNA was detectable with mDC1
showing the lowest mRNA levels indicated by the highest delta Ct
values (Figure 6). However, the observed differences were not
statistically significant. ESE-3j could not be detected in any blood
DC population (data not shown).
Discussion
We previously reported that the epithelial specific Ets
transcription factor ESE-3 is upregulated in moDC stimulated
with different compounds whereas IL-10 treatment inhibiting DC
development from monocytes also impedes induction of ESE-3
expression [15]. Here we pursued the study and analyzed ESE-3
isoforms ESE-3a, ESE-3b and ESE-3j in various immunogenic
and tolerogenic moDC populations and blood DC populations.
We first focused on the cellular localization of the two isoforms
ESE-3a and ESE-3b. It was shown previously that ESE-3 is
localized in the nucleus [31], but the antibody used did not
discriminate between the different isoforms. We therefore tran-
siently expressed EGFP-fused ESE-3a and ESE-3b constructs in
HeLa cells. Both isoforms were detectable only in the nuclei of
transfected cells (Figure 2). As none of the isoforms contain a
nuclear localization signal, the Ets domain itself might be involved
in the nuclear localization as shown previously for the Ets
transcription factor PU.1 [39]. The exclusive localization of all
ESE-3 isoforms in the nucleus suggests that ESE-3 is not directly
regulated via cytoplasmic factors inhibiting its nuclear localization
as described for Ets factor Elf-1 [40] and the NF-kB family of
transcription factors [41].
We then analyzed expression of the different ESE-3 isoforms in
various immunogenic and tolerogenic moDC populations to
elucidate if different expression patterns of ESE-3 could be linked
to the functionally different DC populations. We used TLR4
ligand LPS, TLR3 ligand polyI:C and the Jonuleit cytokine
cocktail most commonly used in today’s DC-based tumor vaccines
consisting of IL-1b, IL-6, TNF-a and PGE2 [42] for the
generation of immunogenic DC. Tolerogenic moDC were
generated with PGJ2 or Dex/VD3. The manipulation of DC
with PGJ2 in vitro has been described as a potential way for the
generation of tolerogenic DC [43]. The addition of a combination
of dexamethasone and vitamin D3 during DC generation has also
been reported to induce tolerogenic DC [12,44,45]. In animal
models, therapeutic vaccination with these cells has been shown to
decrease disease severity and inhibit progression of arthritis [46].
Figure 6. ESE-3b is the only ESE-3 isoform transcribed in blood
DC. MDC1, mDC2 and pDC were isolated from PBMC by positive
selection with magnetic beads. Quantitative real-time RT-PCR using
isoform specific primer/probes was used to analyze mRNA levels of ESE-
3a and ESE-3b. GAPDH was used for normalization. No signal for ESE-3a
was detected. N = 5.
doi:10.1371/journal.pone.0049577.g006
ESE-3b is the Main ESE-3 Isoform in Human DC
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In our experiments, all three immunogenic moDC populations
showed significantly increased levels of ESE-3b mRNA compared
to immature moDC. In contrast, ESE-3b transcription was
downregulated in the two tolerogenic DC populations
(Figure 5A, B). Our findings are in line with our previous results
and point out the importance of ESE-3 in immunogenic DC
development. However, in the previous study we did not
differentiate between ESE-3a and ESE-3b mRNA levels. Since
upregulation of ESE-3b levels was induced by different TLR
ligands as well as under pro-inflammatory conditions using the
Jonuleit cytokine cocktail, it seems that upregulation of ESE-3b
expression in immunogenic DC is not restricted to a certain
maturation stimulus. Our findings are in agreement with previous
reports showing induction of ESE-3 expression by pro-inflamma-
tory cytokines like IL-1b and TNF-a in epithelial cells [27,47].
Also the downregulation of ESE-3b in tolerogenic moDC
populations was independent of the compound used to generate
the cells. In accordance with our previous findings where we
showed that reduction of ESE-3 during generation of moDC using
siRNA leads to an impaired phenotype with remaining expression
of CD14 and reduced expression of CD1a, HLA-DR and CD86
[15], the tolerogenic moDC populations analyzed in the present
study showed remaining CD14 expression and reduced CD1a and
HLA-DR surface expression (Figure 3) with low amounts of ESE-
3b present. In all moDC population ESE-3a was expressed at
much lower levels than ESE-3b (Figure 4B). In contrast to ESE-3b,
ESE-3a mRNA levels were similar in immature and immunogenic
moDC (Figure 5A). These results suggest that ESE-3a has not the
same important role in development of immunogenic moDC as
ESE-3b.
In general, the amount of mRNA does not necessarily correlate
with the amount of protein as there are multiple possibilities of
posttranscriptional regulations. Concerning ESE-3, previous stud-
ies using prostate cancer cells did not always reveal a direct
correlation between ESE-3 mRNA levels and cellular protein
content [31,32]. In our experiments, upregulation of ESE-3b
mRNA was accompanied by a high protein-level of ESE-3b. Both,
at mRNA and protein level, ESE-3b followed the same expression
pattern in the different moDC populations (Figure 5B, C). This
suggests that ESE-3 gene expression rather than post-transcrip-
tional regulation is responsible for the availability of ESE-3b
protein in the nucleus. ESE-3a was not detectable at protein level,
probably due to the lower sensitivity of Western blotting compared
to quantitative real-time RT-PCR.
The third isoform described, ESE-3j, could not even be detected
at mRNA level in any of the analyzed DC populations. Since the
existence of ESE-3j has not been experimentally confirmed yet,
further analyses are needed to verify the actual existence of this
proposed ESE-3 isoform.
In order to establish the biological relevance of ESE-3
expression in DC, we extended our analyses to three DC
populations directly isolated from peripheral blood. ESE-3b
mRNA was detectable in mDC1, mDC2 and pDC (Figure 6)
whereas ESE-3a was not detectable in any blood DC population.
However, all blood DC populations had lower ESE-3b mRNA
levels compared to immature moDC indicated by higher delta Ct
values.
Our findings suggest that ESE-3b is the functionally most
important ESE-3 isoform in DC making this an exciting target to
enhance the immunostimulatory capacity of moDC used in
immunotherapy.
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